Key Insights

Highlights

Treatment Research

1 treatments under study, led by Immunomodulatory Dc Vaccine To Target Dipg And Gbm

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03914768Phase 1Not Yet RecruitingPrimary

Immune Modulatory DC Vaccine Against Brain Tumor

Showing all 1 trials

Research Network

Common Treatments

  • Immunomodulatory Dc Vaccine To Target Dipg And Gbm1

Active Sponsors

  • Shenzhen Geno-Immune Medical Institute1

Top Investigators

Activity Timeline